Trial · NCT04117945
Adverse events416
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 416
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm A (Regorafenib) | 1 | 12 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Arm B (Cetuximab, Panitumumab, Irinotecan) | 5 | 10 | 13 |
| other | Anemia | Blood and lymphatic system disorders | Crossover From Arm A | 3 | 4 | 5 |
| other | Anemia | Blood and lymphatic system disorders | Crossover From Arm B | 3 | 8 | 3 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Arm A (Regorafenib) | 1 | 12 | 1 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Arm B (Cetuximab, Panitumumab, Irinotecan) | 0 | 10 | 0 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Crossover From Arm A | 1 | 4 | 1 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Crossover From Arm B | 0 | 8 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm A (Regorafenib) | 1 | 12 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm B (Cetuximab, Panitumumab, Irinotecan) | 0 | 10 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Crossover From Arm A | 0 | 4 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Crossover From Arm B | 0 | 8 | 0 |
| other | Dry eye | Eye disorders | Arm A (Regorafenib) | 0 | 12 | 0 |
| other | Dry eye | Eye disorders | Arm B (Cetuximab, Panitumumab, Irinotecan) | 0 | 10 | 0 |
| other | Dry eye | Eye disorders | Crossover From Arm A | 1 | 4 | 2 |
| other | Dry eye | Eye disorders | Crossover From Arm B | 0 | 8 | 0 |
| other | Ascites | Gastrointestinal disorders | Arm A (Regorafenib) | 0 | 12 | 0 |
| other | Ascites | Gastrointestinal disorders | Arm B (Cetuximab, Panitumumab, Irinotecan) | 0 | 10 | 0 |
| other | Ascites | Gastrointestinal disorders | Crossover From Arm A | 1 | 4 | 1 |
| other | Ascites | Gastrointestinal disorders | Crossover From Arm B | 0 | 8 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04117945/events